What is KDNA Life Sciences?
KDNA Life Sciences operates as a comprehensive tissue bank, focusing on the provision of life-enhancing orthobiologics. Its specialized applications span spinal, oral/maxillofacial, and sports medicine sectors. Since its inception, KDNA has been instrumental in facilitating over 200,000 tissue grafting procedures, demonstrating a significant impact on patient care and surgical outcomes. The company is committed to advancing tissue grafting practices through its proprietary products and services, targeting healthcare professionals and medical practices engaged in orthobiologics and tissue transplantation.
How much funding has KDNA Life Sciences raised?
KDNA Life Sciences has raised a total of $100K across 1 funding round:
Debt
$100K
Debt (2025): $100K with participation from US Bank
Key Investors in KDNA Life Sciences
US Bank
US Bank, a prominent financial institution, provided debt financing to KDNA Life Sciences, indicating a structured approach to capital allocation for the company's growth initiatives.
What's next for KDNA Life Sciences?
The recent large-scale, late-stage funding positions KDNA Life Sciences for accelerated expansion and innovation. This strategic investment is anticipated to fuel the company's efforts in enhancing its product development pipeline, expanding its service offerings, and potentially exploring new market segments within the orthobiologics and regenerative medicine industries. The company's focus on improving grafting practices suggests a continued emphasis on research and development, aiming to solidify its leadership in the tissue banking sector and capitalize on the growing demand for advanced biological solutions.
See full KDNA Life Sciences company page
